Experimental CAR T-Cell therapy targets tough blood cancers
NCT ID NCT03938987
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized cell therapy called CAR T-cells for people with relapsed or hard-to-treat lymphoma or acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back. The trial aims to find the best dose and evaluate safety and effectiveness in 63 participants aged 2 to 70.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR T-cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat lymphoma or leukemia.
- What could go wrong
- This is an early-phase trial with only 63 participants, so results may not apply to everyone. Side effects can be serious, including immune reactions and nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ADULT ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alberta Children's Hospital
NOT_YET_RECRUITINGCalgary, Alberta, T3B6A8, Canada
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G1Z2, Canada
-
Foothills Medical Centre
NOT_YET_RECRUITINGCalgary, Alberta, T2N2T9, Canada
-
Stollery Children's Hospital
NOT_YET_RECRUITINGEdmonton, Alberta, T6G2B7, Canada
-
Tom Baker Cancer Centre
NOT_YET_RECRUITINGCalgary, Alberta, T2N4N2, Canada
-
University of Alberta Hospital
RECRUITINGEdmonton, Alberta, T6G2B7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for tough lymphoma cases
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough lymphoma
- Supercharged immune cells take on tough B-Cell cancers in early trial
- New immune cell boost may shield kids from Post-Transplant infections
- 15-Year safety check for caribou cell therapy patients